HUP9702409A3 - 1,4,5-trisubstituted imidazole derivatives useful as cytokine, intermediates, preparation and use thereof, pharmaceutical compositions containing these compounds - Google Patents

1,4,5-trisubstituted imidazole derivatives useful as cytokine, intermediates, preparation and use thereof, pharmaceutical compositions containing these compounds

Info

Publication number
HUP9702409A3
HUP9702409A3 HU9702409A HUP9702409A HUP9702409A3 HU P9702409 A3 HUP9702409 A3 HU P9702409A3 HU 9702409 A HU9702409 A HU 9702409A HU P9702409 A HUP9702409 A HU P9702409A HU P9702409 A3 HUP9702409 A3 HU P9702409A3
Authority
HU
Hungary
Prior art keywords
cytokine
intermediates
compounds
preparation
pharmaceutical compositions
Prior art date
Application number
HU9702409A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of HUP9702409A2 publication Critical patent/HUP9702409A2/hu
Publication of HUP9702409A3 publication Critical patent/HUP9702409A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
HU9702409A 1995-01-09 1996-01-11 1,4,5-trisubstituted imidazole derivatives useful as cytokine, intermediates, preparation and use thereof, pharmaceutical compositions containing these compounds HUP9702409A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36996495A 1995-01-09 1995-01-09
US08/472,366 US5593992A (en) 1993-07-16 1995-06-07 Compounds

Publications (2)

Publication Number Publication Date
HUP9702409A2 HUP9702409A2 (hu) 1999-05-28
HUP9702409A3 true HUP9702409A3 (en) 1999-06-28

Family

ID=27004764

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9702409A HUP9702409A3 (en) 1995-01-09 1996-01-11 1,4,5-trisubstituted imidazole derivatives useful as cytokine, intermediates, preparation and use thereof, pharmaceutical compositions containing these compounds

Country Status (34)

Country Link
US (5) US5593992A (hu)
EP (2) EP1264827A1 (hu)
JP (2) JP3330952B2 (hu)
CN (1) CN1138546C (hu)
AP (1) AP1270A (hu)
AR (1) AR002267A1 (hu)
AT (1) ATE254613T1 (hu)
AU (1) AU705207C (hu)
BG (1) BG63769B1 (hu)
BR (1) BR9606904A (hu)
CA (1) CA2209938A1 (hu)
CZ (1) CZ215897A3 (hu)
DE (1) DE69630777T2 (hu)
DK (1) DK0809499T3 (hu)
DZ (1) DZ1961A1 (hu)
ES (1) ES2210348T3 (hu)
FI (1) FI972901A (hu)
HK (1) HK1003623A1 (hu)
HU (1) HUP9702409A3 (hu)
ID (3) ID23273A (hu)
IL (7) IL116455A (hu)
IN (3) IN184957B (hu)
MA (1) MA23770A1 (hu)
MX (1) MX9705142A (hu)
NO (3) NO973167L (hu)
NZ (1) NZ301204A (hu)
OA (1) OA10738A (hu)
PL (1) PL322249A1 (hu)
PT (1) PT809499E (hu)
RU (2) RU2196139C2 (hu)
SI (1) SI0809499T1 (hu)
SK (1) SK90297A3 (hu)
TW (1) TW523511B (hu)
WO (1) WO1996021452A1 (hu)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
DE69421624T2 (de) * 1993-09-17 2000-07-20 Smithkline Beecham Corp Medikamente bindendes protein
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
MX9705296A (es) * 1995-01-12 1997-10-31 Smithkline Beecham Corp Compuestos novedosos de imidazol 1,4,5-susbtituidos y el uso de los mismos para preparar composiciones para uso en terapia.
EP0737471A3 (fr) * 1995-04-10 2000-12-06 L'oreal Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
US5658903A (en) * 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US6369068B1 (en) 1995-06-07 2002-04-09 Smithkline Beecham Corporation Amino substituted pyrimidine containing compounds
FR2740341B1 (fr) * 1995-10-26 1997-12-19 Oreal Utilisation de sel de lanthanide, d'etain, de zinc, de manganese, d'yttrium, de cobalt, de baryum, de strontium dans une composition pour la peau
ZA9610687B (en) 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
NZ327044A (en) * 1996-01-11 2000-01-28 Smithkline Beecham Corp Substituted imidazole compounds
AP9700912A0 (en) * 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
US6372741B1 (en) * 1996-03-08 2002-04-16 Smithkline Beecham Corporation Use of CSAID™ compounds as inhibitors of angiogenesis
JP2000507558A (ja) * 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Ｃｎｓ損傷についての新規な治療
WO1998007425A1 (en) 1996-08-21 1998-02-26 Smithkline Beecham Corporation Imidazole compounds, compositions and use
DE69728688T2 (de) 1996-11-19 2004-08-19 Amgen Inc., Thousand Oaks Aryl und heteroaryl substituierte kondensierte pyrrole als entzündunghemmende mittel
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
AP999A (en) * 1997-01-10 2001-08-11 Smithkline Beecham Corp Novel substituted imidazole compounds.
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
US6432947B1 (en) * 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
UA65572C2 (en) 1997-04-24 2004-04-15 Ortho Mcneil Pharm Inc Substituted imidazoles, intermediate compounds for the preparation thereof, a method for the preparation of substituted imidazoles and a method for the treatment of inflammatory diseases
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
WO1998052941A1 (en) 1997-05-22 1998-11-26 G.D. Searle And Co. PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
US6087496A (en) * 1998-05-22 2000-07-11 G. D. Searle & Co. Substituted pyrazoles suitable as p38 kinase inhibitors
WO1998052937A2 (en) * 1997-05-22 1998-11-26 G.D. Searle And Co. 4-aryl-3(5)-heteroaryl substituted pyrazoles as p38 kinase
NZ501714A (en) 1997-06-12 2001-09-28 Rhone Poulenc Rorer Ltd Imidazolyl-cyclic acetal derivatives, resins and intermediates thereof and use as TNF inhibitors
JP2002504909A (ja) 1997-06-13 2002-02-12 スミスクライン・ビーチャム・コーポレイション 新規な置換ピラゾールおよびピラゾリン化合物
EP0994870A4 (en) 1997-06-19 2002-10-23 Smithkline Beecham NEW IMIDAZOLE COMPOUNDS SUBSTITUTED BY AN ARYLOXYREST
US6040320A (en) * 1997-06-30 2000-03-21 Ortho-Mcneil Pharmaceutical, Inc. 2-substituted imidazoles useful in the treatment of inflammatory diseases
AR016294A1 (es) * 1997-07-02 2001-07-04 Smithkline Beecham Corp Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
WO1999001452A1 (en) * 1997-07-02 1999-01-14 Smithkline Beecham Corporation Novel cycloalkyl substituted imidazoles
US7301021B2 (en) * 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
TW517055B (en) * 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
US6362193B1 (en) 1997-10-08 2002-03-26 Smithkline Beecham Corporation Cycloalkenyl substituted compounds
EP1021173A1 (en) * 1997-10-10 2000-07-26 Imperial College Innovations Limited Use of csaid?tm compounds for the management of uterine contractions
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US7041694B1 (en) 1997-12-17 2006-05-09 Cornell Research Foundation, Inc. Cyclooxygenase-2 inhibition
WO1999032121A1 (en) * 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
TR200003472T2 (tr) 1998-05-22 2001-09-21 Smithkline Beecham Corporation Yeni 2-alkil ikameli imidazol bileşikler
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
JP2002516325A (ja) * 1998-05-26 2002-06-04 スミスクライン・ビーチャム・コーポレイション 新規な置換イミダゾール化合物
WO2000001688A1 (fr) * 1998-07-02 2000-01-13 Sankyo Company, Limited Composes heteroaryle a cinq elements
US6207687B1 (en) * 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
EP1112070B1 (en) 1998-08-20 2004-05-12 Smithkline Beecham Corporation Novel substituted triazole compounds
AU1909200A (en) * 1998-11-04 2000-05-22 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
US6239279B1 (en) 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
EP1140083A4 (en) 1999-01-08 2004-01-02 Smithkline Beecham Corp NEW CONNECTIONS
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
JP2003502424A (ja) * 1999-06-17 2003-01-21 シオノギ バイオリサーチ コーポレイション Ｉｌ−１２産生の阻害物質
IL137365A0 (en) * 1999-07-21 2001-07-24 Sankyo Co Heteroaryl-substituted pyrrole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
AU1781601A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
DE60020595T2 (de) 1999-11-23 2006-03-16 Smithkline Beecham Corp. 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
US6759410B1 (en) * 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
ATE305787T1 (de) 1999-11-23 2005-10-15 Smithkline Beecham Corp 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
ES2236007T3 (es) * 1999-12-08 2005-07-16 Pharmacia Corporation Composiciones de inhibidor de ciclooxigenasa-2 ue tiene un efecto terapeutico rapido.
US20020002169A1 (en) 1999-12-08 2002-01-03 Griffin John H. Protein kinase inhibitors
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US6525051B2 (en) 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
AU5754701A (en) * 2000-07-13 2002-01-30 Pharmacia Corp Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2mediated disorders
HUP0302068A3 (en) 2000-07-20 2005-05-30 Lauras As Use of cox-2 inhibitors for treating or preventing immunodeficiency and pharmaceutical compositions containing them
CZ20031125A3 (cs) 2000-10-23 2003-10-15 Smithkline Beecham Corporation Nové sloučeniny
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
ATE377598T1 (de) 2001-01-22 2007-11-15 Sankyo Co Durch bicyclische aminogruppen substituierte verbindungen
MXPA03008727A (es) 2001-03-26 2004-07-30 Johnson & Johnson Procedimiento para la preparacion de derivados de imidazol tetrasubstituidos y estructuras cristalinas novedosas de los mismos.
US7695736B2 (en) 2001-04-03 2010-04-13 Pfizer Inc. Reconstitutable parenteral composition
WO2002094267A1 (fr) * 2001-05-24 2002-11-28 Sankyo Company, Limited Preparation pharmaceutique pour prevenir ou traiter l'arthrite
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
HUP0401949A3 (en) * 2001-10-22 2009-07-28 Mitsubishi Tanabe Pharma Corp 4-imidazolin-2-one derivatives
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
US6982259B2 (en) * 2002-04-30 2006-01-03 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
WO2004004725A2 (en) 2002-07-09 2004-01-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
US7268139B2 (en) 2002-08-29 2007-09-11 Scios, Inc. Methods of promoting osteogenesis
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
UA80296C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
DE60334016D1 (de) 2002-11-05 2010-10-14 Glaxo Group Ltd Antibakterielle mittel
KR101060215B1 (ko) * 2002-12-16 2011-08-29 아스트라제네카 유케이 리미티드 피리미딘 화합물의 제조 방법
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
CL2004000366A1 (es) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
BRPI0417543A (pt) * 2003-12-12 2007-03-27 Wyeth Corp quinolinas úteis no tratamento de doença cardiovascular
CA2550064A1 (en) * 2003-12-18 2005-07-07 Pfizer Products Inc. Methods of treating acute inflammation in animals with p38 map kinase inhibitors
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
JP4792396B2 (ja) * 2004-08-31 2011-10-12 三洋化成工業株式会社 界面活性剤
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
US7479558B2 (en) * 2005-03-25 2009-01-20 Glaxo Group Limited Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives
PE20100737A1 (es) 2005-03-25 2010-11-27 Glaxo Group Ltd Nuevos compuestos
EP1871770A1 (en) * 2005-04-22 2008-01-02 Kalypsys, Inc. Ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
PT2021335E (pt) 2006-04-20 2011-07-25 Janssen Pharmaceutica Nv Compostos heterocíclicos como inibidores de c-fms quinase
ES2565238T3 (es) 2006-04-20 2016-04-01 Janssen Pharmaceutica N.V. Inhibidores de la c-fms quinasa
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
CN101821393A (zh) * 2007-06-05 2010-09-01 美国西联生物制药公司 诱导t细胞细胞因子的表面分子和使用方法
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
EP2393514B1 (en) * 2009-02-06 2017-12-20 Sichuan Huiyu Pharmaceutical Co., Ltd. Dual inhibition of immunophilin/cyclophilin and emmprin immunoglobulin receptor superfamily members
US9303046B2 (en) 2012-08-07 2016-04-05 Janssen Pharmaceutica Nv Process for the preparation of heterocyclic ester derivatives
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
EP2885293B1 (en) * 2012-08-16 2016-07-27 Janssen Pharmaceutica, N.V. Substituted pyrazoles as n-type calcium channel blockers
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
CN104402823B (zh) * 2014-11-05 2016-03-23 上海浩登材料科技有限公司 一种1，2-二甲基咪唑的制备方法
CN104496906B (zh) * 2014-11-05 2016-03-23 上海浩登材料科技有限公司 一种咪唑的制备方法
CN113350353A (zh) 2015-03-23 2021-09-07 墨尔本大学 呼吸性疾病的治疗
AU2018262108A1 (en) * 2017-05-03 2019-11-21 The University Of Melbourne Compounds for the treatment of respiratory diseases
CA3128468A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN113272298A (zh) * 2018-11-07 2021-08-17 墨尔本大学 用于治疗呼吸系统疾病的化合物和组合物
FR3097222B1 (fr) * 2019-06-11 2021-05-28 Michelin & Cie Nouveaux composes 1,3-dipolaires comprenant un heterocycle aromatique et un cycle imidazole

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725399A (en) * 1969-03-11 1973-04-03 Glaxo Lab Ltd METHOD OF PRODUCING 7{62 -ACYLAMIDO-3-METHYLCEPH-3-Em-4-CARBOXYLIC ACID ESTERS
US3707475A (en) * 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3929807A (en) * 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
US3940486A (en) * 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US4058614A (en) * 1973-12-04 1977-11-15 Merck & Co., Inc. Substituted imidazole compounds and therapeutic compositions therewith
US4199592A (en) * 1978-08-29 1980-04-22 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-2-nitroimidazoles
GR75287B (hu) * 1980-07-25 1984-07-13 Ciba Geigy Ag
US4503065A (en) * 1982-08-03 1985-03-05 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
US4565875A (en) * 1984-06-27 1986-01-21 Fmc Corporation Imidazole plant growth regulators
US4686231A (en) * 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
IE59893B1 (en) * 1986-04-16 1994-04-20 Roussel Uclaf Process for the manufacture of n-(sulfonylmethyl) formamides
IL83467A0 (en) * 1986-08-15 1988-01-31 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
EP0563286A4 (en) * 1990-12-13 1995-01-11 Smithkline Beecham Corp Novel csaids
WO1992010190A1 (en) * 1990-12-13 1992-06-25 Smithkline Beecham Corporation Novel csaids
EP0624159B1 (en) * 1992-01-13 1998-11-25 Smithkline Beecham Corporation Pyridyl substituted imidazoles
IL104369A0 (en) * 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
ZA945363B (en) * 1993-07-21 1995-03-14 Smithkline Beecham Corp Novel compounds
MX9705296A (es) * 1995-01-12 1997-10-31 Smithkline Beecham Corp Compuestos novedosos de imidazol 1,4,5-susbtituidos y el uso de los mismos para preparar composiciones para uso en terapia.

Also Published As

Publication number Publication date
US5663334A (en) 1997-09-02
HUP9702409A2 (hu) 1999-05-28
IL134323A (en) 2001-11-25
CZ215897A3 (cs) 1998-04-15
US6222036B1 (en) 2001-04-24
ID23273A (id) 1996-10-10
DE69630777T2 (de) 2004-07-29
TW523511B (en) 2003-03-11
DE69630777D1 (de) 2003-12-24
IN188338B (hu) 2002-09-07
US20020188122A1 (en) 2002-12-12
NO20016226D0 (no) 2001-12-19
BG63769B1 (bg) 2002-12-29
CN1138546C (zh) 2004-02-18
IN188339B (hu) 2002-09-07
FI972901A (fi) 1997-09-08
ES2210348T3 (es) 2004-07-01
IL134324A (en) 2001-08-26
US6103936A (en) 2000-08-15
EP1264827A1 (en) 2002-12-11
BG101727A (en) 1998-03-31
NO20016226L (no) 1997-09-08
AP1270A (en) 2004-04-16
JP3330952B2 (ja) 2002-10-07
SK90297A3 (en) 1998-01-14
OA10738A (en) 2002-12-11
DZ1961A1 (fr) 2002-02-17
CN1177299A (zh) 1998-03-25
JPH10512555A (ja) 1998-12-02
CA2209938A1 (en) 1996-07-18
AP9701021A0 (en) 1997-07-31
AU4657296A (en) 1996-07-31
AU705207B2 (en) 1999-05-20
AU705207C (en) 2002-09-19
NO973167L (no) 1997-09-08
NO973167D0 (no) 1997-07-08
US5593992A (en) 1997-01-14
SI0809499T1 (en) 2004-04-30
IL116455A (en) 2001-07-24
WO1996021452A1 (en) 1996-07-18
IN184957B (hu) 2000-10-07
DK0809499T3 (da) 2004-03-29
MX9705142A (es) 1997-10-31
JP2002105047A (ja) 2002-04-10
AR002267A1 (es) 1998-03-11
MA23770A1 (fr) 1996-10-01
PL322249A1 (en) 1998-01-19
ID23597A (id) 1996-10-10
HK1003623A1 (en) 1999-02-12
EP0809499A1 (en) 1997-12-03
IL116455A0 (en) 1996-03-31
IL134322A0 (en) 2001-04-30
ATE254613T1 (de) 2003-12-15
EP0809499B1 (en) 2003-11-19
BR9606904A (pt) 1997-10-21
RU2196139C2 (ru) 2003-01-10
NO20016225L (no) 1997-09-08
IL134322A (en) 2001-09-13
PT809499E (pt) 2004-04-30
NZ301204A (en) 1999-05-28
EP0809499A4 (en) 1998-10-14
NO20016225D0 (no) 2001-12-19
RU2002122174A (ru) 2004-02-27
IL134324A0 (en) 2001-04-30
FI972901A0 (fi) 1997-07-08
ID23599A (id) 1996-10-10
IL134323A0 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
HUP9702409A3 (en) 1,4,5-trisubstituted imidazole derivatives useful as cytokine, intermediates, preparation and use thereof, pharmaceutical compositions containing these compounds
HUP9701169A3 (en) Cycloalkano-pyridine derivatives, intermediates, preparation and use thereof, pharmaceutical compositions containing these compounds
HUP9901159A3 (en) Substituted benzylaminopiperidine derivatives and use thereof, pharmaceutical compositions containing these compounds
HUP9802822A3 (en) Halobenzimidazol derivatives, intermediates, preparation thereof and microbocide compositions containing these compounds as active ingredients
HUP9901244A3 (en) 3-pyrazolecarboxamide derivatives having cannabinoid receptor affinity, intermediates, preparation and use thereof, pharmaceutical compositions containing these compounds
HUP9901243A3 (en) Quinazoline derivatives, preparation and use thereof, pharmaceutical compositions containing these compounds
HUP9700709A3 (en) 1,2-diphenylpyrrole derivatives, use thereof and pharmaceutical compositions containing these compounds
HUP9902460A3 (en) Novel substituted imidazole compounds, their use, method for their preparation and pharmaceutical compositions containing them
AU7820191A (en) New imidazole derivatives, their preparation process, the new intermediates obtained, their use as medicaments and the pharmaceutical compositions containing them
HUP9801556A3 (en) Phenylpyridazinone -derivatives, intermediates, preparation and use thereof and herbicide compositions containing these compounds
HUP9802304A3 (en) Pyridazin-3-one derivatives, intermediates, use thereof, insecticide compositions containing these compounds as active ingredients
AU2002792A (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
HUP9901037A3 (en) Piperazine derivatives,preparation and use thereof, pharmaceutical compositions containing these compounds
HUP9900975A3 (en) Quinoxalinedione derivatives, intermediates, preparation and use thereof, pharmaceutical compositions containing these compounds
HUP9901184A3 (en) Antibacterial benzoxazine and pyrido-oxazine derivatives, intermediates, pharmaceutical compositions containing these compounds, preparation and use thereof
HUT77360A (hu) Apoliprotein-B szintézis inhibitor hatású azolszármazékok, eljárás előállításukra, a vegyületeket tartalmazó gyógyszerkészítmények és intermedierjeik
NZ236582A (en) Azaoxindole derivatives, pharmaceutical compositions and intermediates
HUP9902454A3 (en) Substituted 1,2,3,4-tetrahydronaphthalene derivatives, preparation and use thereof, pharmaceutical compositions containing these compounds
HUP9900567A3 (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase, intermediates, preparation and use thereof, pharmaceutical compositions containing these compounds
HUP9901596A3 (en) Pyrazole derivatives, intermediates, preparation and use thereof, herbicide compositions containing these compounds as active ingredients
HUP9900365A3 (en) N-aryl-1,2,4-triazolin-5-on derivatives, preparation and use thereof, insecticide, arachnicide and nematocide compositions containing these compounds as active ingredients
AU3505093A (en) Novel baccatine III and 10-deacetyl baccatine III derivatives, their preparation, and pharmaceutical compositions containing same
HUP9900865A3 (en) Anti-viral benzimidazole derivatives, preparation and use thereof, pharmaceutical compositions containing these compounds
HUP9802430A3 (en) 2-benzoyl-1,3-dioxo-cyclohexane derivatives, preparation, use and intermediates thereof, herbicide compositions containing these compounds as active ingredients
HUP9901873A3 (en) Benzisoxazole and benzisoxazolidinone derivatives, preparation of the latter, herbicide compositions containing these compounds and use thereof